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Chapter 5  
Abstract 
Background: Antihypertensive drugs are developed and registered on the basis of 
blood pressure lowering efficacy combined with safety. However, their long term 
use aims at preventing cardiovascular morbidity and mortality. It becomes 
increasingly clear that antihypertensive drugs have multiple off-target effects that 
may contribute to its efficacy on cardiovascular outcomes. The aim of the present 
analysis was to assess whether a multiple risk parameter response outcome 
(PRE)score, incorporating the drug’s short-term on-target and off-target effects, 
better predicts the ultimate renal/cardiovascular protection than changes in single 
on-target or off-target effects. 
Methods: Data were used from individuals with type 2 diabetes and nephropathy 
participating in the RENAAL or IDNT trials. A PRE score was developed by 
multivariable Cox regression analysis in the placebo arm of RENAAL and was then 
applied to the baseline and month-6 measurements of the ARB treatment arm of 
RENAAL to predict renal or cardiovascular risk. The net risk difference at these 
time-points after correction for placebo effects indicated the estimated long-term 
drug effect. Subsequently, the obtained PRE score was validated in the IDNT trial. 
Findings: Changes in systolic blood pressure predicted relative risk reductions 
significantly different from the actual observed risk reduction in RENAAL, both for 
renal (5.7%, vs 21.8%, respectively), and cardiovascular outcomes (3.0%, vs 9.2%, 
respectively). However, drug efficacy estimation with the PRE score, that 
incorporated many off-target effects, did not statistically significantly differ from the 
actual risk reduction both for renal (30.1% (95% CI 10.8-49.5) vs 21.8% [6.5-34.5]; 
P = 0.44) and cardiovascular outcomes (9.4% [1.9-17.0] vs 9.2% [-7.6-23.6], P = 
0.98]. Validation of the PRE score in IDNT also accurately predicted the renal 
(26.6% [14.3 - 38.9] vs 26.0% [6.4 - 41.5] P = 0.95) and cardiovascular treatment 
effect (7.9% [1.3 - 14.5] vs 11.9% [-8.4 - 28.5] P = 0.67).  
Interpretation: A PRE score based on month-6 changes in on-target and off-target 
risk markers performs better in estimating effects of antihypertensive drugs on hard 
renal and cardiovascular outcomes than any change in single on-target or off-target 
risk markers. 
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Introduction 
The ultimate public health goal of antihypertensive therapy is to reduce the risk of 
cardiovascular morbidity and mortality.1 Antihypertensive drugs are, however, not 
registered based on their efficacy to reduce the risk of renal or cardiovascular 
events, but are developed and registered based on their blood pressure lowering 
capacity. To this end, the effect of the drug on blood pressure is established in 
short-term studies and is subsequently used to estimate the potential long-term 
renal or cardiovascular protective effect using external data. This process assumes 
firstly that the drug effect on blood pressure (the on-target risk factor) is directly 
associated with a reduction in the risk of renal or cardiovascular complications, and 
secondly, that the drug does not influence other risk factors (off-target risk factors) 
that influence renal or cardiovascular events either positively or adversely. The 
latter assumption has however been challenged by several studies and reviews.2-4 
The Losartan Intervention For Endpoint reduction (LIFE) trial showed that 
the Angiotensin Receptor Blocker (ARB) losartan exerted equal blood pressure 
lowering effects as the β-blocker atenolol but conferred superior cardiovascular 
protective effects.2 The Irbesartan Diabetic Nephropathy Trial (IDNT) showed that 
the ARB irbesartan conferred additional renal protective effects compared to the 
Calcium Channel Blocker amlodipine at equal blood pressure control.3The 
Renoprotection of Optimal Anti-proteinuric Dose (ROAD) trial showed that a supra-
maximal dose of losartan improves the anti-albuminuric response and conferred 
markedly more renoprotection at similar blood pressure control compared with 
losartan at the maximally recommended blood pressure dose.5 These studies 
suggest that antihypertensive drugs, in these examples ARBs, exert additional 
beneficial effects on renal or cardiovascular risk factors, so called off-target effects, 
which contribute to the ultimate long-term effect of the drug. It has, however, also 
been shown that administration of antihypertensive drugs can induce changes in 
risk factors, such as increasing serum potassium, which in fact may increase the 
risk for renal/cardiovascular outcome, thus counteracting the beneficial effects of 
these drugs.6-8 This implies that only focusing on blood pressure, the on-target risk 
factor, may result in a misleading impression of the drug’s protective efficacy. We 
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hypothesize that knowing the short term effect of an antihypertensive on all 
renal/cardiovascular risk markers would allow the composition of a response score 
that better predicts the long term effect of such a drug on the ultimate 
renal/cardiovascular outcome. This may have major consequences for drug 
development, drug registration, and individual patient care and highlights the 
necessity to identify those off-target effects.  
 The aim of the present analysis was firstly to identify off-target effects of an 
ARB and assess the impact of the off-target effect on the ARB’s 
renal/cardiovascular efficacy. Secondly, we aimed to construct a multiple risk 
parameter response outcome (PRE) score based on the short-term (6 months) on-
target and off-target effects of ARBs in order to estimate the effect of the drug on 
long term renal/cardiovascular morbidity and mortality. Thirdly, we compared the 
accuracy of ARB efficacy estimates based on the multiple PRE score with scores 
based on single on-target or off-target risk markers. Finally, we validated the 
accuracy of the PRE score in a separate different trial dataset and in a different 




Data were used from the Reduction of Endpoints in NIDDM with the Angiotensin II 
Antagonist Losartan (RENAAL) and IDNT trials. The rationale, study design and 
outcomes for these trials have been previously published and were almost 
similar.3,9-11 In brief, the overall aim of the trials was to assess the impact of an 
ARB on hard renal (primary endpoint) and cardiovascular outcomes (secondary 
endpoint) by testing losartan 100 mg/day vs placebo in the RENAAL trial and 
irbesartan 300 mg/day vs placebo in the IDNT trial. Individuals in the IDNT trial 
could also be randomly assigned to the calcium channel blocker (CCB) amlodipine 
10 mg/day. Inclusion criteria for both trials were presence of type 2 diabetes, 
nephropathy, and age between 30 and 70 years. Individuals with insulin dependent 
diabetes or renal disease not related to diabetes were excluded in both trials. All 
participants gave written informed consent. Both trials were approved by local 
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medical ethics committees and conducted according to the guidelines of the 
declaration of Helsinki. 
 
Measurements 
In both RENAAL and IDNT, a range of renal and cardiovascular biomarkers were 
measured at baseline and at 6 months intervals thereafter. We designate the term 
biomarker throughout this article for parameters like blood pressure, cholesterol, 
calcium, and phosphate, irrespective whether they are causally related to 
cardiovascular morbidity or mortality. All biomarkers collected at baseline and 
month 6 were used to create the PRE score. All measured biomarkers at month 6 
were selected because we did not know a priori which biomarkers would change 
during ARB therapy and secondly to exclude any potential bias as a result of 
biomarker selection. Changes in on-target and off-target biomarkers after ARB 
treatment were calculated as the difference between the baseline and the 6-month 
value. 6-month values were chosen because most parameters were available at 6-
month and ARB treatment effects were considered fully present. Because total 
cholesterol, hemoglobin, serum albumin, calcium, and phosphate were not 
measured at month 6 in the RENAAL trial, 12-month values were used.  
 
Renal and Cardiovascular Outcomes 
The primary outcome for the present analysis was defined as a composite of a 
confirmed doubling of serum creatinine from baseline (DSCR), serum creatinine > 
6.0 mg/dL (in the IDNT trial), or end-stage renal disease (ESRD). The latter was 
defined as chronic dialysis or renal transplantation. The secondary cardiovascular 
outcome was another endpoint for the present study which was defined in both 
trials as the composite of myocardial infarction, stroke, hospitalization for heart 
failure, revascularization procedures or death related to cardiovascular disease. All 
renal and cardiovascular events were adjudicated by an independent blinded 
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Model Development 
A risk score was developed by estimating the relation between single or multiple 
biomarkers and renal or cardiovascular outcomes in the placebo group of the 
RENAAL trial. The single and multiple risk estimates were subsequently applied to 
the baseline and 6-month measurements of the ARB treatment arm to predict renal 
or cardiovascular risk at both time points. The difference in the estimated risk at 
these time-points in the placebo arm was subtracted from the difference in 
estimated risk in the ARB arm. In doing so we obtained single or multiple PRE 
scores that indicate the long-term renal or cardiovascular risk change conferred by 
ARB treatment, based on either changes in single or multiple biomarkers. To test 
the validity of this approach, the obtained single or multiple PRE scores were 
compared with the actual observed renal or cardiovascular outcomes of the trials. 
Any model shows too optimistic performance from the dataset from which it is 
developed. The risk response scores were therefore externally validated by 
developing the scores in the RENAAL trial and testing them in the IDNT trial. To 
further establish the external validity, the PRE score, developed in the RENAAL 
trial, was used to estimate the renal and cardiovascular effect of the CCB 
amlodipine in the IDNT trial. 
 
Model Evaluation 
The methodology to develop the PRE score assumes that the association between 
biomarkers at baseline and renal or cardiovascular events in the placebo group is 
similar as the association between single or multiple risk markers at 6-month and 
renal or cardiovascular events during ARB therapy. To verify the validity of this 
assumption, we determined whether 6 months ARB treatment modified the 
association between biomarkers and renal or cardiovascular events. We did not 
detect an interaction between the biomarkers and ARB treatment for the renal or 
cardiovascular outcome as tabulated in Table 1. This indicates that ARB treatment 
did not modify the association between single or multiple biomarkers and renal or 
cardiovascular events. Imputation of missing data yielded essentially similar results 
as the main analyses.  
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Statistical Analysis 
Mean and standard deviation were provided for 6-month changes in biomarkers 
and statistical significance for the between group difference was determined based 
on a two-sided t-test. Univariable and multivariable Cox proportional hazard 
regressions were used to determine the relationship between baseline biomarkers 
in the placebo treatment arm and renal or cardiovascular outcome. For individuals 
who experienced more than one renal or cardiovascular event during follow-up, 
survival time to the first relevant endpoint was used in each analysis. Participants 
were censored at their date of death or, for those still alive at the end of follow-up, 
the date of their last clinic visit before the termination of the trials. The multivariable 
Cox analysis included the following biomarkers, systolic blood pressure, urine 
albumin-to-creatinine ratio (UACR), potassium, hemoglobin, uric acid, HbA1c, total 
cholesterol, Body Mass Index, calcium, phosphate, and albumin.  
 
Table 1: ARB therapy during 6 months did not modify the association between biomarker and renal or 
CV outcome in the RENAAL trial. Similar results were obtained in the IDNT trial (data not shown). 
 Renal outcomes  CV outcomes 
 β-coefficient P value  β-coefficient P value 
Systolic BP* treatment 0.01 0.54  0.01 0.32 
Log UACR* treatment 0.10 0.74  0.25 0.07 
Potassium* treatment 0.43 0.30  -0.07 0.78 
Hemoglobin* treatment -0.13 0.35  0.04 0.60 
Uric acid* treatment 0.12 0.42  0.06 0.46 
HbA1c* treatment 0.30 0.09  0.02 0.82 
Cholesterol* treatment -0.01 0.24  0.00 0.61 
BMI* treatment 0.02 0.63  0.03 0.25 
Albumin* treatment -0.73 0.28  -0.48 0.19 
Calcium* treatment 0.10 0.84  0.18 0.51 
Phosphate* treatment 0.85 0.03  0.04 0.84 
Multiple* treatment -0.71 0.51  0.70 0.19 
†Treatment variable indicates whether patients received losartan or placebo 
Abbreviations: BP, blood pressure; CV, cardiovascular; UACR, urine albumin-to-creatinine ratio 
 
Bootstrap methods were applied, repeating the entire modeling with 1000 
independent random samples with replacement, to take into account the variability 
of the point estimates of the regression coefficients of the components of the single 
90 
 
Chapter 5  
and multiple risk scores. To determine the actual observed effect of losartan or 
irbesartan on renal/cardiovascular outcomes, the dichotomous treatment variable 
was used in a Cox regression model and the relative risk reduction was calculated 
as (1- hazard ratio) multiplied by 100%. Bootstrap methods, based on 1000 
replications, were also used to derive the 95% confidence interval of the difference 
between the actual observed and predicted treatment effect. The difference 
between the predicted and observed treatment effect was tested by means of two-
sided t-tests. We verified normal distribution of the predicted treatment effect and 
performed log-transformation if required. Time-dependent Cox regression analysis 
was used to assess the interaction between treatment and biomarkers at baseline 
in the placebo group or 6-month biomarkers in the ARB treatment group with 
renal/cardiovascular outcomes. A two-sided P value of 0.05 indicated statistical 
significance. Analyses were conducted with R 2.14.1 (R Project for Statistical 
Computing www.r-project.org).  
 
Results 
Baseline characteristics between the ARB and placebo groups in the RENAAL trial 
were well balanced.11 Losartan significantly changed multiple off-target renal or 
cardiovascular biomarkers beyond blood pressure. Relative to placebo, losartan 
decreased UACR, total cholesterol, hemoglobin, and uric acid, it increased 
potassium, calcium, albumin, and body mass index, while it had no effect on 
Hba1C and phosphate (Figure 1). 
 
Estimated renal and cardiovascular treatment effect by single and multiple PRE 
scores 
During 3.4 years of follow-up 489 renal and 515 cardiovascular events were 
recorded in the RENAAL trial. Treatment with losartan resulted in a relative renal 
risk reduction of 21.8% (95% CI, 6.5 - 34.5%; P = 0.007) and a relative 
cardiovascular risk reduction of 9.2% (95% CI -7.9 - 23.6%; P = 0.27), as 
represented by the horizontal line in Figure 2A and 2B. Single biomarkers either  
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Figure 1: Change in biomarkers after 6 months placebo, ARB, or CCB treatment in the RENAAL and 
IDNT trials.  












































































































































































**     P <0.001
*      P <0.05
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significantly underestimated or overestimated the actual observed drug effect on 
renal and cardiovascular outcomes (Figure 2A and 2B). In particular, the 6-month 
change in blood pressure, induced by the antihypertensive ARB, significantly 
underestimated the renal and cardiovascular outcome (difference between 
estimated and actual risk reduction was 16.0% for renal and 6.2% for 
cardiovascular outcome). The multiple PRE score (using all biomarker changes at 
6-month) predicted a 3.4 years renal risk reduction of 30.1% (95% CI, 10.8 - 
49.5%). This came close to the observed risk reduction (P = 0.44 for the difference 
in the estimate). The PRE score predicted a 9.4% (95% CI, 1.9 - 17.0%) 
cardiovascular risk reduction which was again nearly equal to the observed 
cardiovascular risk reduction (P = 0.98 for the difference in the estimate; Figure 2A 
and 2B). 
 
External Validation of the PRE score in a separate trial database 
To test the validity of the PRE score we applied it to an external separate trial 
database, the IDNT trial, to estimate the treatment effect of the ARB irbesartan on 
renal and cardiovascular outcomes. Irbesartan caused similar directional changes 
in renal or cardiovascular biomarkers as losartan although the magnitude of these 
changes varied compared with losartan (Figure 1). When we entered the 
irbesartan induced changes in multiple renal or cardiovascular biomarkers in the 
PRE score, developed in RENAAL, the PRE score estimated a 26.6% (95% CI 
14.3 - 38.9%) relative renal risk reduction which was nearly equal to the observed 
relative renal risk reduction of 26.0% (6.4 - 41.5%; P = 0.95 vs predicted drug 
effect; Figure 3A). The PRE score estimated a relative cardiovascular risk 
reduction with irbesartan of 7.9% (1.3 - 14.5%) which did not significantly differ 
from the observed cardiovascular risk reduction of 11.9% (-8.4 - +28.5 %; P = 0.67; 
Figure 3B). 
Development of the PRE score in the IDNT trial and application to the irbesartan 
arm of IDNT or losartan arm of the RENAAL trial yielded essentially similar results 
in that the estimation of the observed treatment effect based on the multiple risk 
response score outperformed scores based on single biomarkers (Supplemental  
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Figure 2. Observed and predicted long-term relative renal and cardiovascular risk change (%) based on 
single and multiple PRE scores. Figure A displays the results for renal outcome and Figure B displays 
the results for cardiovascular outcome. The actual observed treatment effect is indicated by the solid 
line. The predicted treatment effect based on single and multiple PRE scores are shown by the vertical 
bars. The PRE score was developed in the RENAAL trial and applied to the baseline and month-6 
values of the placebo and losartan treatment arm of the RENAAL trial. 
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Figures 1 and 2). A sensitivity analysis using changes in biomarkers at month 12 
provided similar results. 
 
External Validation of the PRE score to Another Antihypertensive Drug Class 
To further establish the external validity of the PRE score, we assessed whether 
the PRE score accurately predicted the treatment effect of the CCB amlodipine on 
renal and cardiovascular outcomes in the IDNT trial. Amlodipine decreased blood  
pressure and potassium compared to placebo at month 6, but did not change other 
biomarkers (Figure 1). Based on the 6-month change in blood pressure alone (the 
on-target parameter) a renal risk reduction was predicted whereas the observed 
renal risk tended to increase with amlodipine (Figure 4A). The PRE score 
estimated a 5.0% (95% CI, -6.6 - 16.6%) relative renal risk increase which did not 
differ from the observed renal risk increase of 11.3% (-10.3 - 38.0%; P = 0.56 vs 
predicted drug effect; Figure 4A). The PRE score estimated a relative 
cardiovascular risk reduction with amlodipine of -1.3% (-4.5 - +1.8%) which did not 
significantly differ from the actual observed cardiovascular risk reduction of -14.6% 
(-30.9 - 5.5%); P = 0.14; Figure 4B). 
 
Discussion 
We confirmed that the ARB losartan exerts multiple off-target effects in individuals 
with type 2 diabetes and nephropathy. These off-target effects are either positively 
or negatively associated with renal/cardiovascular morbidity or mortality. In 
addition, we showed that only using the short-term change in blood pressure, the 
on-target effect of this antihypertensive agent, cannot capture the ultimate effect of 
losartan on renal/cardiovascular morbidity or mortality. In contrast, the PRE score, 
based on short-term drug responses of all (available) on-target and multiple off-
target biomarkers, is accurate in predicting the ultimate long-term drug effect on 
renal or cardiovascular outcomes and performs significantly better than any single 
on-target or off-target biomarker, also in external datasets. 
Often drugs change other biomarkers than the one they are targeted to, so 
called off-target effects. We demonstrated that the antihypertensive agent losartan  
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Figure 3 Validation of the PRE score in the IDNT trial. Figure A displays the results for renal outcome 
and figure B the results for cardiovascular outcome. The PRE score is developed in the RENAAL trial 
and applied to the baseline and month 6 measurements of the irbesartan and placebo arm of the IDNT 
trial. The renal and cardiovascular protective effect based on the short-term change in systolic blood 
pressure (the on-target parameter) is indicated by the light grey bar left. The PRE score based drug 
effect on renal and cardiovascular outcomes is shown by the grey bar in the middle. The actual 
observed drug effect on renal and cardiovascular outcomes in the IDNT trial is indicated by the dark 
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does not only lower blood pressure, but also reduces urine albumin excretion, 
hemoglobin, uric acid, and cholesterol, and increases serum potassium, calcium, 
and albumin. Importantly, these different biomarkers vary in their response to the 
drug: blood pressure may decrease whereas potassium does not change or the 
other way around,12,13 and each of these different drug responses are associated 
with renal or cardiovascular morbidity or mortality change.6,14-16 It is therefore not 
surprising that a combination of changes in on-target and off-target multiple 
biomarkers more accurately captures the long-term drug effect than changes in 
single on-target or off-target biomarkers.  
The blood pressure lowering effect of losartan markedly underestimated 
the renal/cardiovascular protective effects of these drugs despite the fact that these 
drugs are developed and registered as antihypertensive drugs. Recent trials have 
shown that this phenomenon is not limited to ARBs, but is applicable to other 
antihypertensive drugs or drug-combinations,17-20 and even extends to other drugs 
used in cardiovascular risk management as well,21-23 as recently reviewed.24 Taken 
together, these trials exemplify that the magnitude of renal or cardiovascular 
protection conferred with antihypertensive agents, or other drugs used to decrease  
cardiovascular risk, cannot always be determined from their on-target drug effect 
but depends on the composite effect on all on-target and off-target biomarkers. Of 
note, while in the ARB example the observed renoprotective effect is larger than 
estimated from blood pressure alone, in the CCB example the actual 
renoprotective effect is less than estimated from blood pressure alone. The latter 
situation has been observed for other drugs as well. For example, in the case of 
rosiglitazone, the actual long-term cardiovascular drug effect is less than estimated 
from the reduction in HbA1c.21,25  
The PRE score uses multiple risk parameters as is done in many other risk 
estimation engines like the Framingham, UKPDS, or more recent ADVANCE risk 
engine. What is the advantage of the PRE score? Traditional risk engines in 
patients with diabetes such as the UKPDS or the more recent ADVANCE risk 
engine only include traditional cardiovascular risk factors and are based on a 
minimal number of readily available clinical lab parameters to predict individual 
prognosis.26,27The PRE score is based on many other biomarkers that are  
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Figure 4: Validation of the PRE score in the IDNT trial for the CCB amlodipine. Figure A displays the 
results for renal outcome and figure B the results for cardiovascular outcome. The PRE score is 
developed in the RENAAL trial and applied to the baseline and month 6 measurements of the 
amlodipine and placebo arm of the IDNT trial. The renal and cardiovascular protective effect based on 
the short-term change in systolic blood pressure (the on-target parameter) is indicated by the light grey 
bar left. The PRE score based drug effect on renal and cardiovascular outcomes is shown by the grey 
bar in the middle. The actual observed drug effect of amlodipine on renal and cardiovascular outcomes 
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influenced by drug therapy and determine the outcome of the individual, thus 
increasing the accuracy of the estimates. Indeed, models based on blood pressure, 
Hba1c and cholesterol alone only predicted ~10% renal and ~2% relative 
cardiovascular risk reductions in the RENAAL trial. In addition, the PRE score does 
not include age and sex as they are non-modifiable.  
The present study may have implications for drug development, drug 
registration and individual patient care. As far as drug development is concerned, a  
multiple on-target and off-target PRE score enables more accurate drug efficacy 
assessment on renal/cardiovascular morbidity and mortality by evaluating the 
short-term effect of the drug on a prefixed set of biomarkers. This will then help to 
determine which drugs have the potential to reach the market in early stages of 
drug development, even before long-term trials are conducted. Novel tools to better 
estimate drug efficacy is highly needed because attrition rates in late phase drug-
development are still approximately 50% and are mostly attributable to drug 
inefficacy (66%).28 As far as drug registration is concerned, drugs are registered 
based on the target of interest. The on-target effects are well measured, recorded 
and evaluated, whereas the off-target drug effects are usually measured as safety 
biomarkers in trials, meaning less rigorous measurements. The PRE score requires 
that all biomarker effects are measured rigorously. A multiple PRE score including 
on-target and off-target drug effects will have the advantage to enable more 
accurate drug efficacy assessment, which can guide the drug regulator to make 
well informed decisions about drug marketing authorization. Finally, the PRE score 
may offer the physician and the patient a better tool to estimate the overall 
prescribed drug effect on long-term outcomes. In case the PRE score has not 
changed sufficiently after starting medication, decisions can be made to increase 
the dose or change the drugs guided by the single components of the PRE score. 
This could make the PRE score particularly relevant for the patient-clinician 
dialogue. 
Several aspects of the model should be considered. As with many 
prediction analyses, the model depends on the biomarkers measured in the trials. 
A PRE score consisting of multiple laboratory parameters accurately predicted 
long-term renal and cardiovascular drug effects. Nevertheless, we cannot exclude 
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that additional biomarkers that offset each other were not incorporated in the model 
and we have only used all biomarkers that were measured in these trials. 
Secondly, the underlying assumption of the model is that the relation between a 
biomarker and renal or cardiovascular outcome is not modified by drug treatment. 
In other words, the relation between a cardiovascular and outcome in the placebo 
group is similar to the relation between a cardiovascular and outcome after 6 
months ARB treatment. We verified the correctness of this assumption in our 
analyses. Thirdly, the accuracy of the PRE score depends of the background 
database such as its size, event rate, its accuracy, and the variation in the levels of 
multiple biomarkers. The current analyses were derived from the placebo arm of 
the RENAAL trial. This can be improved by increasing the placebo treated 
background database. The PRE score is applied to ARB and CCB treatment in 
patients with diabetes and nephropathy. No inferences can be made about the 
performance of the score to predict long-term effects of other drugs in other 
disease areas. Fourthly, the trials were not sufficiently powered to detect 
statistically significant treatment effects on cardiovascular outcomes, compromising 
the precision of the observed and predicted cardiovascular treatment effects. In 
particular, the amlodipine arm in the IDNT trial was merely used to ascertain blood 
pressure independent effects of irbesartan.10 The trial was not powered to detect 
significant treatment effects of amlodipine, which may explain the lack of precision 
in the effect size. Yet, the PRE score estimates of amlodipine showed no effect on 
the renal or cardiovascular outcomes which were in line with the observed 
treatment effects. Strengths of this study are the large size of the trials, the 
availability of many biomarkers at baseline and after 6 months follow-up, the 
validation of the score in a separate independent population, and the similarity of 
the predicted and observed effect sizes.  
 In conclusion, measuring only the short-term blood pressure effect of ARB 
treatment, the on-target parameter, may result in misinterpretations in estimating 
the long-term renal and cardiovascular protective effect. This can have major 
impact on drug registration, individual patients, and society. The PRE score based 
on multiple on-target and off-target biomarkers is accurate in predicting the long-
term outcome of ARB in patients with diabetes and nephropathy. This may not only 
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apply for the studied drugs. Future studies should be directed towards other drugs 
and indications with known off-target effects. 
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Supplemental Figure 1A and 1B: PRE score development in the IDNT trial and application to the 
baseline and month 6 measurements of the placebo and irbesartan treatment arm of the IDNT trial 
(figure A renal outcomes; figure B cardiovascular outcomes).  
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Supplemental Figure 2A and 2B: Validation of the PRE score in the RENAAL trial by applying the 
IDNT developed PRE score to the baseline and month 6 measurements of the placebo and losartan 
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